GlassScriptPhysician profile
David P Brost
NPI 1699757682
$6,716.62
in general payments reported to CMS, 2019-2025
51 companies · $2,540 in 2025
The $2,540 reported for 2025 was more than what 94% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $364 · 2022: $1,391 · 2023: $834 · 2024: $1,587 · 2025: $2,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,454 · Education: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,454.13 |
| Education | $507.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $573.83 | 2021-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals LP | $573.27 | 2021-2025 | Imfinzi, Lynparza, Enhertu |
| Pfizer INC. | $467.70 | 2021-2025 | |
| Incyte Corporation | $424.11 | 2022-2025 | Jakafi, Monjuvi, Niktimvo |
| Janssen Biotech, INC. | $414.36 | 2021-2025 | Carvykti, Rybrevant, Erleada |
| Novartis Pharmaceuticals Corporation | $403.40 | 2021-2025 | |
| Astellas Pharma US INC | $345.25 | 2021-2025 | Padcev, Xospata, Vyloy |
| E.R. Squibb & Sons, L.L.C. | $292.24 | 2021-2025 | Opdivo |
| Exelixis INC. | $266.05 | 2024-2025 | Cabometyx |
| Amgen INC. | $238.78 | 2021-2025 | Vectibix, Kyprolis, Blincyto |
| Aveo Pharmaceuticals, INC. | $218.29 | 2022-2025 | Fotivda |
| Genentech USA, INC. | $201.02 | 2021-2025 | Tecentriq, Alecensa, Itovebi |
| Emd Serono, INC. | $192.80 | 2024 | |
| Seagen INC. | $180.47 | 2022-2025 | Padcev, Adcetris, Tukysa |
| Abbvie INC. | $148.56 | 2022-2025 |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $145.20 | 2025 | |
| Genzyme Corporation | $134.31 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $124.46 | 2022-2025 | Libtayo |
| Takeda Pharmaceuticals U.S.A., INC. | $107.44 | 2022-2025 | Ninlaro, Iclusig, Fruzaqla |
| Celgene Corporation | $104.73 | 2022-2025 | Reblozyl, Sprycel |
| Daiichi Sankyo INC. | $99.00 | 2024-2025 | Injectafer, Enhertu |
| Eisai INC. | $86.18 | 2022-2025 | |
| Gilead Sciences, INC. | $74.49 | 2023-2025 | Trodelvy |
| Celltrion USA INC. | $60.59 | 2025 | Vegzelma |
| Blueprint Medicines Corporation | $59.93 | 2021-2025 | Ayvakit |
| Progenics Pharmaceuticals, INC. | $56.78 | 2025 | |
| Glaxosmithkline, LLC. | $55.84 | 2022-2025 | Ojjaara |
| Kyowa Kirin, INC. | $47.00 | 2023-2024 | Poteligeo |
| Caris Mpi, INC. | $45.71 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $43.42 | 2022 | |
| Pharming Healthcare, INC. | $43.22 | 2022-2023 | Ruconest |
| Sumitomo Pharma America, INC. | $41.37 | 2024 | Orgovyx |
| Alexion Pharmaceuticals, INC. | $38.68 | 2022-2025 | Ultomiris |
| Stemline Therapeutics INC. | $37.51 | 2024-2025 | Orserdu |
| Lilly USA, LLC | $36.48 | 2022-2025 | Verzenio |
| Sobi, INC | $34.62 | 2023 | |
| Rigel Pharmaceuticals, INC. | $30.98 | 2024 | Tavalisse, Rezlidhia |
| Bayer Healthcare Pharmaceuticals INC. | $30.34 | 2024-2025 | |
| Myovant Sciences INC. | $27.71 | 2022 | |
| Beigene USA, INC. | $27.45 | 2023-2024 | Brukinsa |
| Pharmacyclics LLC, An Abbvie Company | $26.64 | 2021-2023 | Imbruvica |
| Geron Corporation | $18.24 | 2025 | Rytelo |
| Novocure INC. | $16.16 | 2025 | Optune Gio |
| Azurity Pharmaceuticals, INC. | $16.16 | 2025 | Danziten |
| Adaptive Biotechnologies Corporation | $16.00 | 2022 | |
| Alnylam Pharmaceuticals INC. | $15.98 | 2024 | Amvuttra |
| Pharmaessentia USA Corporation | $15.88 | 2024 | Besremi |
| Springworks Therapeutics, INC. | $15.64 | 2025 | Gomekli |
| Acrotech Biopharma INC. | $15.20 | 2025 | Beleodaq |
| Foundation Medicine, INC. | $14.99 | 2022 | |
| Array Biopharma INC | $12.16 | 2025 | Mektovi, Tukysa, Braftovi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Brost listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.